BioDelivery Sciences International (BDSI +3%) gets a boost from a Piper Jaffray upgrade to...

|About: BioDelivery Sciences Intern... (BDSI)|By:, SA News Editor

BioDelivery Sciences International (BDSI +3%) gets a boost from a Piper Jaffray upgrade to Overweight. Piper calls BDSI a value-added offering for pain and expects Phase III bioequivalence data for Bunavail to show a possible superiority to its other generic opioid dependence treatment Suboxone. Bunavail's NDA filing is planned for July and Phase III readout is expected by year-end or early 2014.

Subscribe for full text news in your inbox